ACG Releases New Idiosyncratic Drug-Induced Liver Injury Guidelines
released new clinical guidelines for the diagnosis and treatment of idiosyncratic drug-induced liver injury.
The guidelines include an overview of risk factors, diagnostic tools, casualty assessment, prognosis factors and management of hepatotoxicity. DILI incidence is on the rise and the guidelines are designed to help physicians diagnose and manage the rare, difficult-to-diagnose adverse drug reaction.
The guidelines focus on herbal and dietary supplements due to the overall lack of regulation. Traces of heavy metals and prescription drugs have been found in some herbal and dietary supplements, according to guidelines co-author Herbert L. Bonkovsky, MD, FACG.
More Articles on Gastroenterology:
Can Independent GI Practices Survive & Thrive?
11 GI-Driven ASCs & Facilities Opened in 2014
Mayo Clinic Winds Award for Cologuard: 5 Things to Know
© Copyright ASC COMMUNICATIONS 2014. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
New From Becker's GI & Endoscopy
Is there a new colon cancer marker?Read Now
- 12 tips to negotiate a deal more effectively
- ASC stock report — 5 key company updates
- New EndoChoice slim scope, US Endoscopy distribution agreement & more – 6 GI/endoscopy company key notes
- VisionCare completes financing for commercialization of telescope implant
- House committee chairmen release joint statement on ICD-10 implementation